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A B S T R A C T   
Objectives: Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for pa-
tients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). 
However, such studies often exclude patients treated in routine clinical practice. We report interim results from a 
Phase 3b, open-label, multicenter, single-arm, exploratory trial, in which afatinib was investigated in a real- 
world setting. 
Materials and methods: Patients with EGFRm + tyrosine kinase inhibitor (TKI)-naïve NSCLC received afatinib 
40 mg orally, once-daily, until disease progression, or voluntary withdrawal. Primary objective was safety. 
Results: Overall, 479 patients received afatinib: median age 65 years, 8 % of patients had an ECOG performance 
status ≥ 2, 17 % had brain metastases, and 13 % had tumors containing uncommon mutations only. All but one 
patient (99.8 %) had an adverse event (AE). Treatment-related AEs (TRAEs; any/grade ≥ 3) occurred in 97 %/44 % 
of patients; most common were diarrhea (87 %/16 %) and rash (51 %/11 %). AEs leading to afatinib dose-reduction 
were reported in 258 patients (54 %), and 37 patients (8 %) discontinued treatment due to a TRAE. Objective 
response rate was 45.5 %, median duration of response was 14.1 months (95 % CI: 12.2–16.4). Overall median time 
to symptomatic progression and progression-free survival were 14.9 months (95 % CI: 13.8–17.6) and 13.4 months 
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(95 % CI: 11.8–14.5), respectively, in the overall population and 19.3 months (95 % CI: 15.6–21.8) and 15.9 months 
(95 % CI: 13.9–19.1) in patients with EGFR exon 19 deletions. 
Conclusions: Afatinib administration in routine clinical practice was well tolerated with no new safety signals and 
demonstrated promising efficacy in patients with EGFRm + NSCLC. TRAEs were generally manageable with 
tolerability-guided dose reductions. Overall, these data independently support findings from randomized 
controlled trials of afatinib in EGFRm + NSCLC.   
1. Introduction 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer- 
related mortality globally, accounting for approximately 1.7 million 
deaths in 2018 [1]. Despite advances in the treatment of NSCLC in recent 
decades, current therapy options are still associated with poor survival 
[2]. Chemotherapy, the historical standard of care, typically delays 
NSCLC disease progression by only a few months and can be associated 
with considerable toxicity [3]. However, the identification of numerous 
oncogenic driver mutations in recent years has allowed the development 
of targeted therapies based on the molecular characteristics of individ-
ual tumor types. Immune checkpoint inhibitors are now the standard of 
care, either alone or with chemotherapy, in patients with tumors 
harboring no epidermal growth factor receptor (EGFR), ALK, or other 
molecular aberrations [4]. 
Up to 50 % of Asian [5] and 10–15 % of Caucasian patients [6] with 
NSCLC have tumors that harbor mutations in the EGFR gene [7]. The 
most common mutations within this gene are exon 19 deletions (Del19) 
and the L858R point mutation (L858R), which account for approxi-
mately 90 % of all EGFR mutations [8,9]. First-, second-, and 
third-generation EGFR tyrosine kinase inhibitors (TKIs) are available as 
first-line treatment options for patients with EGFR mutation-positive 
(EGFRm +) NSCLC tumors [10–14]. 
Unlike first-generation (erlotinib or gefitinib) EGFR TKIs, second- 
generation (afatinib and dacomitinib) ErbB family inhibitors bind irre-
versibly to EGFR, ErbB2 and ErbB4, and block transphosphorylation of 
ErbB3 to inhibit all ErbB family signaling [15,16]. Randomized 
controlled trials (RCTs) have demonstrated that second and 
third-generation EGFR TKIs have improved efficacy, compared with 
first-generation TKIs in this setting [17–19]. In Phase 3 RCTs (LUX-Lung 
3 and 6) [20], treatment with afatinib resulted in a significant 
improvement in overall survival (OS) vs chemotherapy in patients 
whose tumors harbored Del19 mutations (LUX-Lung 3: 33.3 vs 21.1 
months; LUX-Lung 6: 31.4 vs 18.4 months) [21]. Furthermore, treat-
ment with afatinib, compared with treatment with standard chemo-
therapy, improved PFS in the overall population (LUX-Lung 3: median: 
11.1 vs 6.9 months, HR: 0.58; LUX-Lung 6; median: 11.0 vs 5.6 months, 
HR: 0.28), including those with uncommon mutations [22]. In the 
randomized Phase 2b LUX-Lung 7 trial [19], afatinib significantly 
improved progression-free survival (PFS; median: 11.0 vs 10.9 months, 
HR: 0.73, p = 0.017), objective response rate (ORR; 70 % vs 56 %, odds 
ratio 1.873, p = 0.0083) and time-to-treatment failure (TTF; median: 
13.7 vs 11.5 months, HR: 0.73, p = 0.0073) compared with gefitinib in 
patients with Del19/L858R EGFRm + NSCLC. However, no significant 
difference in OS was observed with afatinib vs gefitinib (27.9 vs 24.5 
months; HR: 0.86, p = 0.26) [23]. Across these RCTs, patients treated 
with afatinib experienced EGFR TKI class-related toxicities (diarrhea, 
rash/acne, stomatitis, nail effects), which were successfully managed 
with tolerability-guided dose reductions [19,20]. 
RCTs are conducted with strict inclusion criteria that often exclude 
patients with certain characteristics commonly observed in the routine 
clinical practice (real-world), such as older age, brain metastases, un-
common mutations, prior chemotherapy treatment, or Eastern Cooper-
ative Oncology Group performance status (ECOG PS) ≥ 2. Real-world 
studies, which include patients with a range of characteristics, including 
those excluded from clinical trials, can generate additional data to help 
clinicians make evidence-based treatment decisions for a wider range of 
patients than traditional RCTs. This is particularly important as the 
treatment landscape for EGFRm + NSCLC evolves, with greater focus on 
determining the optimal treatment sequence [24]. 
The current study is a real-world study of afatinib in patients with 
EGFRm + NSCLC. The aim was to evaluate the safety and efficacy of 
afatinib in EGFR TKI-naïve patients with locally advanced or metastatic 
NSCLC harboring EGFR mutation(s), who are reflective of everyday 
clinical practice. We present here an interim analysis, conducted 4 years 
after recruitment was completed. 
2. Materials and methods 
2.1. Study design 
This is a Phase 3b, open-label, multicenter, single-arm, exploratory 
trial of afatinib in EGFR TKI-naïve patients with locally advanced or 
metastatic EGFRm + NSCLC. The trial was conducted at 119 sites within 
Europe, Australia, Russia and Israel (see Supplementary material A for 
all enrolling countries). The protocol was updated after recruitment was 
completed to specify that an interim analysis could be conducted once 
patient recruitment was complete. The study was carried out in 
compliance with the protocol, the principles laid down in the Declara-
tion of Helsinki, in accordance with the ICH Harmonised Tripartite 
Guideline for Good Clinical Practice (GCP) and relevant Boehringer 
Ingelheim Standard Operating Procedures (SOPs). Patients were 
required to give written informed consent, prior to admission into the 
trial. 
The study is registered at Clinical trials.gov number NCT01853826 
and the European Union Clinical Trials register EudraCT number 2009- 
017661-34. 
2.2. Patients and treatment 
The study enrolled patients (aged ≥ 18 years) with histologically 
confirmed, locally advanced or metastatic EGFRm + (locally assessed) 
NSCLC, with an ECOG PS of ≤ 2, adequate organ function and no prior 
use of EGFR TKI treatment. Patients were excluded if they had received 
anti-cancer treatment within 2 weeks prior to start of trial treatment, or 
had symptomatic brain metastases. All EGFR mutation types were 
permitted (see Supplementary material B for additional criteria). 
Patients received oral afatinib 40 mg, once-daily, until disease pro-
gression, lack of tolerability or other reasons necessitating withdrawal. 
Study treatment could be continued beyond radiological progression 
only (without symptomatic progression) until clinical progression, if it 
was deemed in the patient’s benefit following a careful risk-benefit 
assessment and confirmation of clinical benefit by the investigator. 
Treatment-related adverse events (TRAEs) were managed by 
tolerability-guided dose modifications. In the event of any drug related 
AE of grade ≥ 3, or persistent grade 2 diarrhea, or grade ≥ 2 renal 
dysfunction, treatment was paused until the patient recovered to grade 
≤ 1 or baseline, before treatment was resumed with dose reduction of 
10 mg decrements. If the patient could not tolerate 20 mg/day, or the 
patient did not recover to grade ≤ 1 or baseline within 6 weeks, treat-
ment was discontinued. Concomitant therapies, including anesthetic 
agents, vitamins, homeopathic/herbal remedies and nutritional sup-
plements, were allowed and were recorded from the date of informed 
consent to the follow-up visit. 
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2.3. Endpoints and assessments 
The primary objective was to evaluate safety. Primary endpoints 
included AEs, coded according to Medical Dictionary for Drug Regula-
tory Activities (MedDRA version 21.0) and graded using the National 
Cancer Institute Common Terminology Criteria for Adverse Events 
version 3.0, evaluated by investigator assessment. Safety evaluation 
visits were conducted after administration, and every 28 (-7/+2) days 
until withdrawal. The secondary objective was to determine the efficacy 
of afatinib. Secondary endpoints included: time to symptomatic pro-
gression (TTSP; defined as the time from first administration of afatinib 
to the date of first documented clinically significant symptomatic pro-
gression [symptoms get worse or disease spreads to other parts of the 
body]), PFS, ORR and duration of response, disease control rate (DCR) 
and duration of disease control, as judged by the investigator. Efficacy 
analyses were based on the assessment of cancer related symptoms and, 
if available, radiologic assessments as per standard of care at the 
participating institution and determined by Response Evaluation 
Criteria in Solid Tumors (RECIST). 
EGFR mutations were detected according to the EGFR mutation 
testing methodology used in each participating institution. 
2.4. Statistical analyses 
All patients who received at least one dose of afatinib (treated set) 
were included in the safety and efficacy analyses. Subgroup analysis of 
TTSP and PFS was conducted according to ECOG PS, brain metastases at 
baseline (presence/absence), line of therapy and EGFR mutation type 
(Del19/L858R/uncommon). Descriptive statistics are presented; no 
hypotheses testing was planned, and all analyses were exploratory. 
3. Results 
3.1. Patients, disposition, and treatment exposure 
At data cut-off for the interim analysis (30th July 2018), 479 patients 
had received afatinib. Patient baseline characteristics are shown in 
Table 1. Most patients were Caucasian (97 %) and the median age was 
65 years (range: 25–89) with 50 % of patients aged ≥ 65 years. An ECOG 
PS of 2 was reported in 36 (8 %) patients and 83 (17 %) patients had 
brain metastases. The most common histological classification was 
adenocarcinoma in 95 % of patients. In total, 416 (87 %) had NSCLC 
harboring common EGFR mutations, and 62 (13 %) patients had tumors 
containing uncommon mutations only, the most frequent of which were 
insertions in EGFR exon 20, which were detected in 37 of 62 (60 %) of 
these tumors. Afatinib was most commonly used as a first-line therapy 
(78 %) and 126 (26 %) patients had previously received systemic 
chemotherapy. 
Overall, 452 (94 %) patients discontinued treatment; the most 
common reason for treatment discontinuation was progressive disease 
in 331 (69 %; Fig. 1) patients. The median duration of treatment across 
all lines of afatinib was 11.8 months (range: 0.07–55.4 months). 
3.2. Efficacy 
3.2.1. TTSP (overall and by subgroup) 
The overall median TTSP was 14.9 months (95 % CI: 13.8–17.6; 
Fig. 2A). Median TTSP was numerically longer in patients with no 
baseline brain metastases (15.8 months) compared with those with brain 
metastases at baseline (13.7 months; Fig. 2B). Median TTSP was also 
numerically longer in patients with an ECOG PS of 0 or 1 (15.8 months) 
compared with an ECOG PS of 2 (8.9 months; Fig. 2B); in patients 
receiving afatinib as first-line (15.6 months) or second-line therapy 
(14.7 months) compared with those receiving ≥ third-line afatinib (8.1 
months; Fig. 2B); and in those whose tumors harbored common EGFR 
mutations Del19 only (19.3 months) and L858R only (14.5 months), 
compared with those whose tumors contained uncommon mutations 
(7.4 months; Fig. 2B). TTSP was similar regardless of age. 
3.2.2. PFS (overall and by subgroup) 
The overall median PFS was 13.4 months (95 % CI: 11.8–14.5; 
Fig. 3A). Median PFS was numerically longer in patients who had no 
baseline brain metastases (13.9 months), in comparison with those with 
brain metastases at baseline (10.1 months; Fig. 3B). Median PFS was also 
longer in patients with an ECOG PS of 0/1 (13.8 months) compared with 
those with an ECOG PS of 2 (6.2 months; Fig. 3B); in patients receiving 
afatinib as first-line (13.8 months) and second-line therapy (13.2 
Table 1 
Baseline demographics and disease characteristics.  
Characteristic Afatinib (n = 479) 
Sex, n (%)  
Female 314 (65.6) 
Median age, years (range) 65 (25–89) 
≥ 65 years, n (%) 241 (50.3) 
≥ 75 years, n (%) 92 (19.2) 
Race, n (%)  
White 465 (97.1) 
Asian 10 (2.1) 
Othera 4 (0.8) 
Smoking status, n (%)  
Never smoked 305 (63.7) 
Ex-smoker 143 (29.9) 
Current smoker 31 (6.5) 
Baseline ECOG PS, n (%)  
0 171 (35.7) 
1 271 (56.6) 
2 36 (7.5) 
Missing 1 (0.2) 
Histological classification, n (%)  
Predominantly adenocarcinoma 457 (95.4) 
Predominantly squamous cell carcinoma 7 (1.5) 
Large cell/undifferentiated carcinoma 9 (1.9) 
Missing 3 (0.6) 
Not otherwise specified 3 (0.6) 
Clinical stage at diagnosis, n (%)  
I–II 49 (10.2) 
IIIA 39 (8.1) 
IIIB 33 (6.9) 
IV 357 (74.5) 
Missing 1 (0.2) 
Prior lines of therapy  
First 374 (78.1) 
Second 81 (16.9) 
Third 18 (3.8) 
≥ Fourth 6 (1.3) 
EGFR mutation category, n (%)  
Exon 19 deletions onlyb 232 (48.4) 
L858R onlyb 162 (33.8) 
Any uncommonc 84 (17.5) 
Exon 20 insertionsd 37 (7.7) 
G719S, G719A, G719Cd 12 (2.5) 
T790Md 12 (2.5) 
L861Qd 10 (2.1) 
S768Id 9 (1.9) 
Otherd 18 (3.8) 
Number of metastatic sites, n (%)  
0 17 (3.5) 
1 121 (25.3) 
2 136 (28.4) 
≥ 3 204 (42.6) 
Missing 1 (0.2) 
Metastases at screening, n (%)  
Brain 83 (17.3) 
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance 
status; EGFR, epidermal growth factor receptor. 
a Other: 1 Native Hawaiian or other Pacific Islander; 3 Black/African 
American. 
b Del19 or L858R mutations only (i.e., no uncommon mutations). 
c Uncommon EGFR mutations with/without common mutations. 
d Patients can appear in more than one mutation category. 
F. de Marinis et al.                                                                                                                                                                                                                             
Lung Cancer 152 (2021) 127–134
130
months) compared to those receiving afatinib as ≥ third-line therapy 
(6.6 months; Fig. 3B); and in those patients whose tumors harbored the 
common EGFR mutations, Del 19 (15.9 months) and L858R (13.1 
months) compared with those whose tumors contained uncommon 
mutations (6.0 months; Fig. 3B). PFS was similar regardless of age. 
3.2.3. ORR and DCR (overall and by subgroup) 
Overall, 218 of 479 patients (45.5 %) demonstrated an objective 
tumor response to afatinib (complete response: 25 [5.2 %]; partial 
response: 193 [40.3 %]; stable disease: 193 [40.3 %]; progressive dis-
ease: 34 [7.1 %]; not evaluable: 23 [4.8 %]; missing: 11 [2.3 %]). Me-
dian duration of response was 14.1 months (95 % CI: 12.2–16.4). 
ORR was highest in patients receiving afatinib as an earlier line of 
therapy either as first-line (49.2 %) or second-line (37.0 %) compared 
with ≥ third-line afatinib therapy (16.7 %; Table 2); however, the 
median duration of response was lower in these patients: 13.8 months 
and 15.7 months as first- or second-line therapy compared with 20.2 
months as ≥ third-line therapy (Table 2). ORR was higher and median 
duration of response was longer in patients whose tumors harbored 
common EGFR mutations only, Del19 (52.6 % and 16.9 months) and 
L858R (43.8 % and 13.2 months), compared with those whose tumors 
harbored uncommon EGFR mutations (28.6 % and 9.3 months; Table 2). 
In the overall population, the DCR was 85.8 % (411/479 patients) 
and median duration of disease control was 14.7 months (95 % CI: 
13.6–16.1). 
DCR was higher in patients receiving afatinib as first-line therapy 
(86.6 %), than in those receiving afatinib as a third-line therapy (79.2 %; 
Table 2); additionally, median duration of disease control was longer in 
the patients receiving afatinib as first line therapy (15.0 and 8.1 months; 
Table 2). However, there were no marked differences in DCR and me-
dian duration of disease control between patients receiving afatinib as a 
first- or second-line therapy (Table 2). 
DCRs were higher and median duration of disease control was longer 
in patients with tumors harboring common mutations, Del19 (90.1 % 
and 17.7 months) L858R (85.2 % and 14.4 months) in comparison with 
those whose tumors harbored uncommon mutations (75.0 % and 8.1 
months; Table 2). 
DCR and ORR were similar between patients with and without brain 
metastases (Table 2). 
3.3. Safety and tolerability 
Most patients (478/479) experienced an AE and grade ≥ 3 AEs were 
reported in 315 patients (66 %). 
Any grade TRAEs and grade ≥ 3 TRAEs were recorded in 462 (97 %) 
and 210 (44 %) patients, respectively (Table 3). The most frequently 
reported (≥ 10 %) any grade TRAEs were diarrhea (87 %), rash (51 %), 
paronychia (30 %), mucosal inflammation (18 %), dry skin (17 %), 
stomatitis (14 %), skin fissures (11 %), nausea (10 %), dermatitis 
acneiform (10 %), and conjunctivitis (10 %). Overall, 8 patients had a 
grade 4 TRAE (dehydration 1; diarrhea 5; fatigue 1; electrolyte imbal-
ance 1). There were two afatinib-related deaths, (grade 5 TRAE) one 
pneumonitis and one intestinal infarction; the intestinal infarction may 
have been caused by either mesenteric embolism or gastrointestinal 
perforation. 
Serious AEs (SAEs) were reported in 202 (42 %) patients; the most 
common were diarrhea and pleural effusion in 16 patients each (3 %), 
whilst 39 (8 %) patients had a treatment-related SAE, the most common 
being diarrhea in 15 (3 %) patients. 
AEs leading to dose reduction of afatinib were reported in 258 (54 %) 
of patients. Dose reductions to 30 mg occurred in 258 (54 %) patients, 
and further dose reductions to 20 mg occurred in 87 (18 %) patients. The 
most frequent AEs leading to dose reduction included diarrhea in 119 
(25 %) patients, and rash in 53 (11 %) patients. AEs leading to discon-
tinuation of afatinib were reported in 105 (22 %) patients, of whom 37 
(8 %) patients experienced TRAEs leading to drug discontinuation; the 
most frequent was diarrhea in 16 patients (3 %). Sixty-nine (14 %) pa-
tients had a SAE that resulted in death; the most common cause was 
malignant neoplasm (6 %). 
4. Discussion 
This was an interim analysis of a Phase 3b, open-label, exploratory 
trial of afatinib in EGFR TKI-naïve patients with locally advanced or 
metastatic EGFRm + NSCLC. The incidence and severity of AEs reported 
were consistent with the known profile of afatinib in EGFRm + NSCLC, 
as observed in the LUX-Lung trials [19,20]. 
Treatment with afatinib resulted in TTSP and PFS times of over 
1 year, with a particularly notable benefit observed among certain pa-
tient subgroups. The high proportion of patients with tumors harboring 
EGFR exon 20 insertions (60 % of patients with tumors harboring un-
common mutations) may at least partly account for the lower PFS and 
TTSP observed in the uncommon mutation subgroup, compared with the 
common mutation groups. As with all EGFR TKIs [25], exon 20 in-
sertions are generally insensitive to afatinib. In a pooled analysis of the 
LUX-Lung 2, 3 and 6 trials, the response rate in patients with exon 20 
insertions (n = 23) was 9% [26]. However, the response rates in patients 
with the major uncommon mutations, G719X (n = 18; 78 %), L861Q 
(n = 16; 56 %) and S768I (n = 8; 100 %) were comparable to those 
typically observed in patients with common EGFR mutations. 
Fig. 1. Patient flow diagram. a4 switched to commercial drug; 3 due to in-
vestigator’s decision; 3 withdrew consent; 3 had a protocol violation,1 required 
prohibited concomitant treatment. 
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ORR and DCR results, overall and across certain subgroups, were 
similarly encouraging, and consistent with findings from previous trials. 
ORR was higher in patients with NSCLC harboring common EGFR mu-
tations, lower ECOG PS and those receiving afatinib as an earlier line of 
therapy. 
Few TRAEs led to discontinuation of afatinib, indicating these events 
were generally tolerable and manageable. While 54 % of patients had 
AEs leading to dose reduction, 22 % of patients discontinued treatment 
due to AEs, and only 8% specifically due to TRAEs. The proportion of 
patients who discontinued due to TRAEs was similar to that observed in 
LUX-Lung 3, 6 and 7 trials (8 %, 6 % and 6 %, respectively). These data 
support the previous findings from LUX-Lung 3, 6 and 7 that afatinib 
TRAEs are largely manageable through tolerability-guided dose reduc-
tion, permitting patients to remain on treatment for as long as possible. 
It has previously been reported that dose reduction does not reduce ef-
ficacy, as shown by sub-analyses of the LUX-Lung 3, 6 and 7 studies [27, 
28]. In addition, these results are generally supported by data from 
real-world studies conducted to date including the observational Real-
GiDo study, assessing afatinib dose adjustment [29]. The key strength of 
the current study is that many patients had characteristics that are often 
seen in routine clinical practice, but that may preclude enrolment in 
randomized controlled trials (including older age, comorbidities, base-
line ECOG PS 2, brain metastases, tumors harboring uncommon EGFR 
mutations). Such studies are becoming more common [26], and gaining 
increasing recognition as a means of expanding clinical experience in 
broad populations that are more reflective of patients encountered in 
everyday clinical practice. Key real-world studies of afatinib treatment 
for EGFRm + NSCLC are summarized in a recent review by Park and 
Yang [26] and include: the observational RealGiDo study [29] which 
reported that dose adjustment of afatinib did not affect efficacy and the 
GioTag study [30,31] which reported that sequential afatinib and osi-
mertinib treatment facilitates prolonged, chemotherapy-free treatment. 
In this study, afatinib had a predictable and manageable safety 
profile in a patient population that is typically encountered in routine 
clinical practice. Interim efficacy findings were also encouraging, with a 
median PFS and TTSP of > 1 year. However, some limitations should be 
noted; this trial was a single arm study, without a control arm, and 
patient numbers in some subgroups were small. 
Overall, the safety and efficacy results from this large Phase 3b study 
independently support findings from previous randomized controlled 
trials of afatinib in EGFRm + NSCLC, including the LUX-Lung 3/6/7 
trials and other real-world studies. Further, ongoing studies of afatinib 
Fig. 2. TTSP A) in all patients (Kaplan–Meier analysis) and B) according to patient subgroups (forest plot). Abbreviations: CI, confidence interval; TTSP, time to 
symptomatic progression. Median, 95 % CI, 25th and 75th percentiles are calculated from unadjusted Kaplan–Meier estimates. 
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in routine clinical practice populations, such as the ongoing Phase 3b 
study among EGFR TKI-naïve Asian patients (NCT01953913) and the 
Phase 4 study among chemotherapy pre-treated patients 
(NCT02208843) will help inform clinicians further. 
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Table 2 
Tumor response in patient subgroups.   
ORR n (%) Median duration of objective response, months (95 % CI) DCR n (%) Median duration of disease control, months (95 % CI) 
Line of therapy     
First 184 (49.2) 13.8 (11.7–16.1) 324 (86.6) 15.0 (13.7–16.8) 
Second 30 (37.0) 15.7 (10.4–21.0) 68 (84.0) 15.1 (11.6–20.7) 
≥ Third 4 (16.7) 20.2 (5.0–29.7) 19 (79.2) 8.1 (5.7–15.2) 
EGFR mutation category     
Del19 only 122 (52.6) 16.9 (13.0–20.1) 209 (90.1) 17.7 (14.7–20.4) 
L858R only 71 (43.8) 13.2 (11.1–16.4) 138 (85.2) 14.4 (12.9–17.3) 
Uncommon 24 (28.6) 9.3 (5.6–12.5) 63 (75.0) 8.1 (6.0–9.0) 
Brain metastases at screening     
Yes 40 (48.2) 11.1 (7.4–16.8) 71 (85.5) 11.6 (8.8–15.1) 
No 178 (45.1) 15.0 (12.9–17.1) 339 (85.8) 15.2 (13.9–17.7) 
Baseline ECOG PS,     
0/1 205 (46.4) 15.0 (12.3–16.9) 385 (87.1) 15.2 (13.9–17.5) 
2 13 (36.1) 8.3 (5.0–14.1) 25 (69.4) 9.1 (5.7–13.9) 
Age,     
<75 189 (48.8) 14.1 (11.7–16.2) 340 (87.9) 15.1 (13.6–16.8) 
≥75 29 (31.5) 16.5 (10.6–21.2) 71 (77.2) 14.1 (11.6–21.4) 
Abbreviations: CI, confidence interval; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor 
receptor; ORR, objective response rate. 
Data are n (%). 
Table 3 
Frequency of treatment-related AEs, all grades and grade ≥ 3 occurring in ≥ 5 % 
of patients of the treated population (n = 479).  
AE, n (%) All grades Grade ≥ 3 
Any TRAE 462 (96.5) 210 (43.8) 
Diarrhea 416 (86.8) 77 (16.1) 
Rash 246 (51.4) 51 (10.6) 
Paronychia 142 (29.6) 17 (3.5) 
Mucosal inflammation 85 (18.2) 12 (2.5) 
Dry skin 79 (16.5) 1 (0.2) 
Stomatitis 67 (14.0) 8 (1.7) 
Skin fissures 51 (10.6) 3 (0.6) 
Nausea 50 (10.4) 5 (1.0) 
Conjunctivitis 50 (10.4) 3 (0.6) 
Dermatitis acneiform 49 (10.2) 8 (1.7) 
Pruritus 46 (9.6) 1 (0.2) 
Asthenia 43 (9.0) 14 (2.9) 
Decreased appetite 39 (8.1) 3 (0.6) 
Vomiting 38 (7.9) 5 (1.0) 
Fatigue 37 (7.7) 8 (1.7) 
Rash papular 34 (7.1) 3 (0.6) 
Skin toxicity 31 (6.5) 7 (1.5) 
Nail disorder 29 (6.1) 4 (0.8) 
Alopecia 26 (5.4) 0 
Abbreviations: AE, adverse event; TRAE, treatment-related adverse events. 
Percentages are calculated using total number of patients (n = 479) as the 
denominator. 
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